How a DNA sequencing start-up proved it is no pushover
TwinStrand co-founder’s grandfather famously didn’t patent the polio vaccine, but Dr Jesse Salk believes that protecting inventions is key to getting products to reach the market
TwinStrand co-founder’s grandfather famously didn’t patent the polio vaccine, but Dr Jesse Salk believes that protecting inventions is key to getting products to reach the market
Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.
Chief Legal Officer Yoori Kim argues that current patent uncertainty should fuel rather than thwart licensing deals
A recent deal shows that a wider selection of corporates are exploring acquisition opportunities and working with custom R&D labs
08 March 2022
Arbutus Biopharma and Genevant Sciences have filed suit against the vaccine innovator
07 March 2022
As the US and European gene-editing IP landscapes drift further apart, therapeutics companies face difficult freedom-to-operate quandaries
03 March 2022
Roivant’s most recent spinout shows that it is still on the hunt for deprioritised life sciences patents
22 February 2022
Petro Terblanche tells IAM about the IP issues surrounding her team’s new replica of Moderna’s covid-19 vaccine
10 February 2022
Versatile biotechnologies are changing patterns of collaboration among healthcare innovators
10 February 2022
EPO Board of Appeal seeks clarification on joint applicants approach to priority rights
04 February 2022
The pair say their strategic cooperation will start with in-house patent prosecution services with the potential to grow from there
02 February 2022
Spate of recent transactions show the value of gene-editing patents beyond Cas9
28 January 2022
Even some of the programme’s architects seem to agree that it has strayed from initial focus on trade secrets and intellectual property
22 January 2022
Unlock unlimited access to all IAM content